Comparative Pharmacology
Head-to-head clinical analysis: CLINDA DERM versus NEOSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDA DERM versus NEOSPORIN.
CLINDA-DERM vs NEOSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
None Documented
None Documented
2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment.
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces).
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic